Laxmi Dental · risk themes across the available quarters.
Bear-case history
China faces 34% tariffs while Laxmi Dental moved from 50-57% down to 25%. Management acknowledged they remain more expensive than Chinese competitors. If tariffs increase again, customer attrition could recur, impacting both revenue and profitability targets.
Q3 underperformance attributed partly to lower US NRI patient inflows in Gujarat/western India belt (45-50% of domestic business). This exposes the business to immigration/travel policy changes and currency-driven demand shifts beyond management control.
Management claimed pricing pressure is 'trending towards normalcy' but provided no quantitative data. The aligner segment (₹16.4 crores, flat YoY) remains under competitive stress, and this claim cannot be verified until Q4 results confirm volume recovery.
When asked whether scanners sold to dentists can be used to send scans to competitor labs, management gave a nuanced answer: minimum volume commitment required but scans can be sent elsewhere above threshold. This competitive risk to the lab network was not proactively raised by management.